Morgan Stanley’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $137M | Buy |
1,487,324
+333,025
| +29% | +$33.4M | 0.01% | 1186 |
|
|
2025
Q4 | $118M | Buy |
1,154,299
+171,755
| +17% | +$15.4M | 0.01% | 1305 |
|
|
2025
Q3 | $61.4M | Buy |
982,544
+95,918
| +11% | +$5.22M | ﹤0.01% | 1842 |
|
|
2025
Q2 | $46.1M | Sell |
886,626
-53,879
| -6% | -$2.41M | ﹤0.01% | 1993 |
|
|
2025
Q1 | $40.1M | Sell |
940,505
-491,911
| -34% | -$21.2M | ﹤0.01% | 2014 |
|
|
2024
Q4 | $43.8M | Sell |
1,432,416
-283,800
| -17% | -$7.98M | ﹤0.01% | 1951 |
|
|
2024
Q3 | $39.4M | Sell |
1,716,216
-305,490
| -15% | -$8.65M | ﹤0.01% | 2083 |
|
|
2024
Q2 | $58.4M | Buy |
2,021,706
+920,114
| +84% | +$21.4M | ﹤0.01% | 1612 |
|
|
2024
Q1 | $22.7M | Sell |
1,101,592
-3,814,972
| -78% | -$81.8M | ﹤0.01% | 2553 |
|
|
2023
Q4 | $133M | Buy |
4,916,564
+2,760,884
| +128% | +$72.4M | 0.01% | 1454 |
|
|
2023
Q3 | $63.9M | Buy |
2,155,680
+429,749
| +25% | +$15.1M | 0.01% | 1359 |
|
|
2023
Q2 | $61.8M | Buy |
1,725,931
+18,367
| +1% | +$527K | 0.01% | 1409 |
|
|
2023
Q1 | $40M | Sell |
1,707,564
-3,507,945
| -67% | -$100M | ﹤0.01% | 1753 |
|
|
2022
Q4 | $142M | Buy |
5,215,509
+222,807
| +4% | +$10.2M | 0.02% | 832 |
|
|
2022
Q3 | $269M | Sell |
4,992,702
-163,494
| -3% | -$8.39M | 0.04% | 471 |
|
|
2022
Q2 | $208M | Sell |
5,156,196
-350,373
| -6% | -$17.4M | 0.03% | 571 |
|
|
2022
Q1 | $365M | Sell |
5,506,569
-314,210
| -5% | -$21.5M | 0.05% | 348 |
|
|
2021
Q4 | $582M | Buy |
5,820,779
+260,138
| +5% | +$26.9M | 0.07% | 254 |
|
|
2021
Q3 | $695M | Buy |
5,560,641
+1,315,317
| +31% | +$156M | 0.09% | 205 |
|
|
2021
Q2 | $527M | Sell |
4,245,324
-180,312
| -4% | -$24.3M | 0.07% | 257 |
|
|
2021
Q1 | $676M | Sell |
4,425,636
-514,248
| -10% | -$77.7M | 0.1% | 200 |
|
|
2020
Q4 | $637M | Sell |
4,939,884
-1,370,694
| -22% | -$158M | 0.1% | 195 |
|
|
2020
Q3 | $705M | Buy |
6,310,578
+335,960
| +6% | +$30.7M | 0.14% | 161 |
|
|
2020
Q2 | $485M | Buy |
5,974,618
+962,740
| +19% | +$77.6M | 0.11% | 176 |
|
|
2020
Q1 | $349M | Sell |
5,011,878
-117,840
| -2% | -$9.04M | 0.09% | 193 |
|
|
2019
Q4 | $401M | Sell |
5,129,718
-290,010
| -5% | -$20.9M | 0.09% | 207 |
|
|
2019
Q3 | $346M | Buy |
5,419,728
+605,362
| +13% | +$53.3M | 0.09% | 217 |
|
|
2019
Q2 | $416M | Buy |
4,814,366
+2,902,471
| +152% | +$222M | 0.11% | 181 |
|
|
2019
Q1 | $147M | Sell |
1,911,895
-203,846
| -10% | -$11.3M | 0.04% | 413 |
|
|
2018
Q4 | $79.5M | Buy |
+2,115,741
| New | +$77.9M | 0.02% | 610 |
|
Other funds holding GH
VPM
VCM
Morgan Stanley's GH Position: Q1 2026 in Review
Morgan Stanley increased its Guardant Health (GH) stake by 29% in Q1 2026, buying an estimated $33.4M and bringing the position to 1,487,324 shares worth $137M. The position accounts for 0.01% of the portfolio, ranked #1186.
Morgan Stanley first reported a position in GH in Q4 2018 and has held it in 30 quarters since. The position peaked at $705M in Q3 2020. 481 funds tracked by Wall St. Rank hold GH as of Q1 2026.
- Morgan Stanley held 1,487,324 shares of Guardant Health worth $137M as of Q1 2026.
- Morgan Stanley bought 333,025 Guardant Health shares in Q1 2026, an estimated $33.4M.
- Guardant Health made up 0.01% of Morgan Stanley's portfolio in Q1 2026, its #1186 holding.
- Morgan Stanley first reported a position in Guardant Health in Q4 2018 and has held it in 30 quarters since.
- Morgan Stanley's Guardant Health position peaked at $705M in Q3 2020.
- 481 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.